The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:
Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
First-time ECMO initiation.
Venoarterial ECMO (VA-ECMO) as the initial mode.
Age <18 years.
Severe pulmonary hypertension.
Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
Severe missing data.
At participating centers, adult patients with cardiogenic shock require venoarterial extracorporeal membrane oxygenation (VA-ECMO) support, meeting specific hemodynamic and end-organ dysfunction criteria.
Cohort
Prospective
Vasopressor Exposure Levels
Other interventionThis is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.
30-Day All-Cause Mortality
The proportion of patients who die from any cause within 30 days following ECMO initiation.
In-Hospital Survival Rate
The proportion of patients who survive to hospital discharge.
ECMO-Related Complications
The incidence of ECMO-related complications, including bleeding, thrombosis, infection, and mechanical failures.
Click on the lead sponsor to view all of their trials.
Xiaotong Hou
Lead sponsor
Beijing Anzhen Hospital
Sponsor institution
